COVID-19 Related Chemosensory Changes in Individuals with Self-Reported Obesity

Authors: Bhutani, S., Coppin, G., Veldhuizen, MG., Parma, V., Joseph, PV

Author Affiliations:

Surabhi Bhutani, School of Exercise and Nutritional Sciences, San Diego State University, San

Diego, CA

Géraldine Coppin, Department of Psychology, Formation Universitaire à Distance

(UniDistance), Brig, Switzerland; Swiss Center for Affective Sciences, University of Geneva,

Geneva, Switzerland; geraldine.coppin@unige.ch

Maria Geraldine Veldhuizen, Department of Anatomy, Faculty of Medicine, Mersin University,

Mersin, Turkey; margaveldhuizen@gmail.com

Valentina Parma, Department of Psychology, Temple University; Monell Chemical Senses

Center; valentina.parma@temple.edu

Paule Valery Joseph, National Institutes of Alcohol Abuse and Alcoholism and National Institute

of Nursing Research paule.joseph@nih.gov

Contact Information:

Surabhi Bhutani, PhD

School of Exercise and Nutritional Sciences

San Diego State University

ENS Building, room 302

5500 Campanile drive

San Diego, CA 92182

Phone: 619-594-4094

sbhutani@sdsu.edu

Running Title: COVID-19 chemosensory decline in obesity

Word Count: 4000

Funding: Deployment of the GCCR survey was supported by an unrestricted gift from James

and Helen Zallie to support sensory science research at Penn State. Paule V. Joseph is supported

by the National Institute of Alcohol Abuse and Alcoholism and the National Institute of Nursing

Research. PVJ is also supported by the Office of Workforce Diversity, National Institutes of

Health, and the Rockefeller University Heilbrunn Nurse Scholar Award. Maria G. Veldhuizen is

supported by the 2232 International Fellowship for Outstanding Researchers Program of

TÜBİTAK under award number 118C299.

Disclosures:

Competing interests: The authors declare no competing financial interests in relation to the

work described.

Author Contributions:

All authors conceived the project idea. MGV and VP analyzed the data. SB, GC, PJ drafted the

manuscript. All authors were involved in editing the paper and had final approval of the

submitted and published versions.

Abstract

Background/objectives: Individuals with obesity show alterations in smell and taste abilities. Smell and taste loss are also the most prominent neurological symptoms of COVID-19, yet how chemosensory ability present in individuals with obesity with a positive COVID-19 diagnosis is unknown.

Subjects/Methods: In this secondary analysis of a cross-sectional global dataset, we compared self-reported chemosensory ability in participants with a respiratory illness reporting a positive (C19+; n = 5156) or a negative (C19-; n = 659) COVID-19 laboratory test outcome, who also self-reported to be obese (C19+; n = 433, C19-; n = 86) or non-obese.

Results: Compared to the C19- group, C19+ exhibited a greater decline in smell, taste, and chemesthesis during illness, though these symptoms did not differ between participants with obesity and without obesity. In 68% of participants who reported recovery from respiratory illness symptoms (n=3431 C19+ and n= 539 C19-), post-recovery chemosensory perception did not differ in C19+ and C19- diagnosis, and by self-reported obesity. Finally, we found that all chemosensory and other symptoms combined predicted the C19+ diagnosis in participants with obesity with a moderately good estimate (63% accuracy). However, in C19+ participants with obesity, we observed a greater relative prevalence of non-chemosensory symptoms, including respiratory as respiratory and GI symptoms.

Conclusions: We conclude that despite a presumed lower sensitivity to chemosensory stimuli, COVID-19 respondents with obesity experience a similar self-reported chemosensory loss as those without obesity, and in both groups self-reported chemosensory symptoms are similarly predictive of COVID-19.

Keywords: COVID-19; Smell; Taste; Chemesthesis; Obesity

INTRODUCTION

According to the World Health Organization, globally 13% of adults aged 18 years and over reported to have obesity in 2016 (1). Within the context of the ongoing COVID-19 pandemic, intriguingly, countries with the highest prevalence of obesity also recorded a high death rate from COVID-19 infection (2). Although, an increased in susceptibility to viral infection with obesity is unknown, a recent review by Stefan et al. concluded that obesity is a strong and independent determinant of morbidity and mortality in patients infected with SARS-CoV-2, the virus responsible for COVID-19 infection (3). A recent analysis also indicated that COVID-19 mortality in patients with obesity is higher than that of other comorbidities, including diabetes, hypertension, asthma, and cancer (4). In addition to greater risk for COVID-19 related poor health outcomes (3,5,6), patients with obesity are more likely to require hospitalization, especially in young adults with a Body Mass Index (BMI) >30 kg/m (7). Overall, current evidence suggests that obesity significantly interacts with the pathogenesis of COVID-19. Despite this risk, COVID-19 chemosensory symptoms have not yet been systematically assessed in this population group.

Disturbances in smell and taste emerged as a predominant neurological symptom of COVID-19 infection, with 77 percent of COVID-19 patients reporting sudden olfactory and gustatory dysfunctions in a recent meta-analysis (8). In a recent analysis, we also reported quantified smell loss as the best predictor of COVID-19, compared to other common non-chemosensory symptoms (9). However, these studies did not delineate COVID-19-related chemosensory impact in patients with obesity. This is especially important because individuals with obesity typically have existing lower taste sensitivity, and lower capacity to detect and identify odors than individuals without obesity (10). Particularly, excessive body weight has

been shown to be associated with impaired taste for sweet and salty foods, alteration in fat/fatty

acid-sensing, reduced ability to identify correct taste (11–13) in taste detection thresholds (11–

15). These obesity-related chemosensory dysfunctions are driven by production of pro-

inflammatory factors from adipose tissues, leading to impairment in olfactory receptors (16) and

a decline in taste bud and taste progenitor cells (17,18), respectively. Considering that marked

inflammation with obesity also seems to favor viral infections (19,20), the interaction between

existing chemosensory deficiency in adults with obesity and COVID-19 related chemosensory

impairments are unknown.

Existing gustatory and olfactory sensory deficiency due to obesity may mask the viral-

induced diminished taste and smell self-reported experiences, leading to a higher portion of

undetected cases in this population (21), we need a better understanding of how chemosensory

profile changes in patients with obesity. Furthermore, in light of the potential for using oro-naso

sensory perception as an early marker of SARS-CoV-2 infection (22–24), it needs to be assessed

whether the predictive relation between the chemosensory loss and COVID-19 illness

generalizes to participants with obesity. With continually increasing death rates projected well

into 2021 using a second statistical model (25), and a wave of infections sweeping through

countries worldwide, it is imperative to understand the impact of SARS-COV-2 virus on

chemosensory dysfunction in COVID-19 patients in the high-risk category such as populations

with excessive body weight. Here, we systematically describe and compare the chemosensory

perception (smell, taste, and chemesthesis) and related symptomatology in COVID-19 in non-

hospitalized adults with or without self-reported obesity. Following our pre-registered analysis

plan (26), we hypothesized that the participants with obesity will report less smell loss during

COVID-19 illness. We also hypothesize that smell loss will be less predictive of COVID-19

diagnosis than the participants without obesity.

METHODS

Study Design

To the best of our knowledge, this study is the first to assess chemosensory alterations in

adults with obesity and COVID-19. We conducted a secondary analysis of cross-sectional

survey data collected between April 7th and November 4th, 2020 using the Global Consortium

for Chemosensory Research (GCCR) core questionnaire. This crowdsourced survey collected

data from community-dwelling individuals via social and traditional media as well as the GCCR

website. It was also presented to clinicians to relay to their patients. This survey, currently

deployed in 32 languages, used binary-response and categorical questions, as well as visual

analog scales to measure self-reported chemosensory ability and other symptoms in adults with

ongoing or recent respiratory illnesses (22). We also collected self-reported data on the presence

of pre-existing diseases, including our condition of interest, obesity, as well as other COVID-19

symptoms All participants included in the study were: 1) ≥18 years old, 2) had a (suspected)

respiratory illness within the past two weeks, 3) had onset of respiratory illness after January 1,

2020, 4) reported COVID-19 diagnosis via laboratory test (viral PCR or antigen test).

Respondents who did not report having any illness or symptoms within the last two weeks, who

had multiple responses, or who responded "Don't know" or "Other" when asked about their

diagnosis of COVID-19, were excluded from the analyses. To investigate the recovery of

chemosensory functions, only participants who reported the date of onset of respiratory illness

symptoms were included. The original study was approved by the Office of Research Protections

of The Pennsylvania State University (STUDY00014904). The hypotheses and analyses in this

manuscript were pre-registered at https://osf.io/xf25v (26) and the research compendium

including data files and analysis scripts is available at https://osf.io/rbcty/. Specifically, our

analyses aimed to describe chemosensory perception and related symptomatology during the

COVID-19 illness (Aim 1) and post-vs pre-COVID-19 diagnosis (Aim 2), in participants with

self-reported obesity vs without obesity. We predicted lower ratings for smell, taste, and

chemesthesis, and more severe COVID-19 symptoms in participants with obesity, compared to

without obesity. We also speculated smaller differences in ratings for smell, taste, and

chemesthesis perception post- vs pre- COVID diagnosis in participants with self-reported

obesity. Post-COVID-19 chemosensory recovery (Aim 3) was also tested, hypothesizing that

participants will have lower ratings for smell, taste, and chemesthesis post-COVID-19 recovery

in participants with self-reported obesity vs without obesity. Additionally, we assessed COVID-

19 severity as measured based on the sum of reported symptoms (Aim 4), and the ability of smell

ratings to predict COVID-19 diagnosis (Aim 5), in participants with self-reported obesity vs

without obesity.

A departure from the pre-registered analyses is the inclusion of age as a factor in all

analyses, following differences in age we observed between groups. We also report the

unregistered analysis of pre-illness ratings, an important addition given the previously reported

decreased sensitivity for participants with obesity compared to those without obesity.

Participant Description

A convenience sample of 52334 volunteers accessed the GCCR questionnaire. Of those

individuals, 5815 met the inclusion and exclusion eligibility criteria and were included in the

final analysis. A positive COVID-19 diagnosis (C19+) was determined using the self-reported

data from COVID-19 lab test or clinical exam outcome. All C19+ patients were further

categorized into having obesity if they reported it as one of the pre-existing disease conditions in

the questionnaire. C19+ patients who did not report having any medical condition or did not

answer this question on pre-existing disease conditions were categorized as controls without

obesity. We also included a control group of participants without obesity. See Figure 1. for a

flow diagram of the inclusion of participants into the various groups.

Statistical Analyses

Statistical analyses were conducted in R (27) via RStudio. The annotated scripts, the

information on the computational environment, and dependencies shared for future

reproducibility will be found, upon acceptance of the manuscript, at the OSF project link, which

includes directions to the GitHub page at which the code is stored.

No negative value appeared in the survey responses. Whenever in question 38 (prior conditions),

no response was provided or the option "None" was checked, the response was imputed as

indicating no prior conditions. Prediction targets were never imputed. All open-ended questions

were excluded as they are incompatible with model generalization.

Demographics

Cognizant of possible null effects in all our analyses, we opted to implement a Bayesian

approach, which allows us to estimate the strength of the evidence supporting the null

hypothesis. To test via a between-participant sequential Bayes factor design whether a difference

between groups was present (H1) or absent (H0), we conducted Bayesian linear regressions with

the lmBF function from the BayesFactor package (28). We used the default Cauchy prior on the

effect sizes under the H1 as the scale parameter spread, which was set at its default value of r =

sqrt (2)/2. To test for a difference in age between groups, we used the following full model: Age

~ COVID diagnosis + Obesity Age + COVID diagnosis x Obesity. Additive models (no

interaction) and main effect models were also computed and compared to determine the model

that best explained the data pattern, aka the model comparison with the most extreme Bayes

Factor. Please refer to **Supplementary Table 1** for the inference rules, which follows the

classification scheme proposed by Lee and Wagenmakers (29) and adjusted from (30). To

interpret the strength and the direction of the effects identified, we have additionally sampled

from the models' posterior distributions (iterations = 1e4). To test for gender differences between

groups, we calculated probability tables of women and men in each of the COVID-19 and

obesity groups and tested for distribution differences with Pearson's chi-square tests with the R

base function "prop.test". We used an alpha of 0.05 to determine significance.

Self-reported Chemosensory perception analyses

For chemosensory perception analyses, we also conducted Bayesian linear regressions

with the lmBF function. The full model included the following terms: Dependent variable ~

COVID diagnosis + Obesity Age + COVID diagnosis x Obesity. Additive models (no

interaction) and main effect models were also computed and compared to determine the model

that best explained the data pattern. Age was included in all models to factor in significant

associations between age and obesity. We used "before illness", "during illness", "change due to

illness" ("before illness" minus "during illness") and "recovery" ("after illness" minus "during

illness") separately as dependent variables.

Other illness symptomatology analyses

To assess whether participants with obesity experience more and/or different symptoms

from those without obesity, we summed all symptoms that participants reported (each symptom

that was reported was assigned a value of 1). We then conducted Bayesian linear regressions

with the lmBF function as above with summed symptoms as the dependent variable (as above in

the chemosensory analyses). We operationalized disease duration as the number of days since

onset of the illness and used "days since onset" as the dependent variable in Bayesian linear

regression (models as above). For the subset of COVID-19 patients only, we calculated

probability tables for the likelihood of experiencing a given symptom for the participants with

and without obesity and tested for distribution differences with chi-square tests (details as above

under demographics). We used an alpha of 0.05 to determine significance.

Model accuracy for predicting COVID-19 illness

To deal with binary classification problems in the presence of imbalanced classes, we

used the ROSE (Random Over-Sampling Examples) package (31), which generates synthetic

balanced samples and thus allows to strengthen the subsequent estimation of any binary

classifier. To measure model quality, receiver operating characteristic (ROC) were visualized via

the pROC package (32) based on the calculation of hold-out area under the curve (AUC), which

summarizes the tradeoff between sensitivity (fraction of correctly identified C19+ cases in the

sample with obesity and without obesity) and specificity (fraction of correctly identified C19-

cases in the sample with obesity and without obesity) as the threshold value for the predictor is

varied. We used symptoms (binary), number of symptoms, chemosensory ratings during illness,

COVID diagnosis, and days since onset of the respiratory illness. We focused on "during illness"

ratings because those best showed evidence for the effects of illness and were also the most

predictive symptom in a previous study with the same questionnaire (9). Moreover, this question

(rather than pre-illness ratings or change in ratings) is best suited for being asked when making

an inventory of symptoms in a clinical setting.

RESULTS

Participant Characteristics

A total of 5156 participants reported a positive lab test for COVID-19 (hereafter, C19+),

while 659 reported a negative lab test for COVID-19 (hereafter, C19-). Of all participants, 519

(9% of the total group) self-reported to have obesity (C19+ = 433; C19- = 86) (**Figure 1**). The

demographic profile of our participants is summarized in **Supplementary Table 2 a and b**. Age

is higher in OB+ compared to OB- (43.1 vs 39.5) (BF_{10} = 7.48e+06 ± 0%). After excluding n =

17 participants with gender reporting categories of "prefer not to say" (n = 13) and "other" (n =

4), we observed different proportions of gender (χ^2 = 4.42, p = 0.035), driven primarily by a

higher proportion of women in the C19- group with obesity (87.2%) compared to those without

obesity (77%).

Before COVID-19 illness, participants with obesity exhibit similar smell, taste, and

chemesthesis loss as those without obesity before COVID-19 illness

Before COVID-19 illness, OB+ participants did not self-report greater ability in smell

(change against zero, BF_{10} = 6.48e-02 ± 0%), taste (BF_{10} = 7.24e-02 ± 0%) or chemesthesis

(BF_{10} = 7.89e-02 ± 0%), or greater nasal congestion (BF_{10} = 6.80e-02 ± 0%) than OB-

participants **(Supplementary Figure 1, Supplementary Table 3)**. Before COVID-19 illness

C19+ participants reported greater ability in smell (BF_{10} = 2.16e+01) and taste (BF_{10} = 3.45e+02

$\pm$ 0%) than C19- participants.

During COVID-19 illness, participants with obesity exhibit similar smell, taste, and

chemesthesis loss as those without obesity during COVID-19 illness

259   C19+ participants reported greater deficits in smell (change against zero: BF_{10} =

1.20e+75 $\pm$ 0%), taste (change against zero: BF_{10} = 1.51e+29 $\pm$ 0%), and chemesthesis (change

against zero: BF_{10} = 1.69e+05 $\pm$ 0%), as compared with C19- participants (**Figure 2,**

Supplementary Table 4). Similar to our previous report (22), we reported lower deficits in nasal

congestion with C19+ participants in our analysis (change against zero: BF_{10} = 1.56e+01 $\pm$ 0%),

compared to C19- participants. Further, these chemosensory variables did not differ between the

participants who self-reported obesity vs participants without obesity (smell BF_{10} = 1.44e-01 $\pm$

0%; taste 5.7e-02 $\pm$ 0%; chemesthesis 8.22e-01 $\pm$ 0%), across the COVID groups.

Similar to the above chemosensory findings during the illness, the differences in chemosensory

ratings between pre-and during illness varied in C19+ and C19- participants (**Figure 3,**

Supplementary Table 5). In particular, C19+ participants reported greater deficits in smell

(change against zero: BF_{10} = 5.18e+59 $\pm$ 0%), taste (change against zero: BF_{10} =1.46e+32 $\pm$ 0%),

and chemesthesis (change against zero: BF_{10} = 6.82e-+07 $\pm$ 0%), than the C19- group. However,

when estimating the effect of obesity condition, the three chemosensory variables did not differ

between the groups with obesity and without obesity across the COVID-19 condition (smell

change against zero; BF_{10} = 6.71e-02 $\pm$ 0%; taste change against zero BF_{10} = 5.28e-02 $\pm$ 0%;

chemesthesis change against zero $BF_{10} = 1.26e\text{-}01 \pm 0\%$). Interestingly, there was no main effect

of COVID-19 condition or obesity status on the nasal obstruction reporting.

Participants with obesity exhibit similar smell, taste, and chemesthesis recovery from

COVID-19 illness as those without obesity

280   To further understand changes in chemosensory perception with COVID-19 diagnosis

and obesity condition, we looked at the data from participants who reported recovery from the

illness (**Figure 4, Supplementary Table 6**). Recovery was reported by 3970 participants

(n=3431 C19+ and n= 539 C19-), which is approximately 68% of our sample. Our Bayesian

linear models suggest that the ratings for post-recovery chemosensory perception (smell $BF_{10} =$

$7.79e\text{-}02 \pm 0.02\%$; taste $BF_{10} = 6.44e\text{-}02 \pm 0.02\%$; chemesthesis $BF_{10} = 2.18e\text{-}01 \pm 0.01\%$) did

not differ in C19+ and C19- diagnosis. Of note, some smell/taste/chemosensory symptoms

remain post-recovery from the illness in C19+ and C19- groups. We found no differences in

smell ($BF_{10} = 6.58e\text{-}02 \pm 0.02\%$), taste ($BF_{10} = 1.07e\text{-}01 \pm 0.02\%$), and chemesthetic perception

($BF_{10} = 9.96e\text{-}02 \pm 0.11\%$) by self-reported obesity. Nasal obstruction did not seem to be

affected by either COVID-19 diagnosis ($BF_{10} = 5.33e\text{-}02 \pm 0.03\%$) or obesity status ($BF_{10}$

$=8.16e\text{-}02 \pm 0.02\%$) post-recovery from the illness.

Participants with obesity report more symptoms overall and more frequently report

respiratory and gastrointestinal (GI) symptoms.

295   Based on the evidence from existing clinical and epidemiological studies, one of our

goals was to assess whether individuals with self-reported obesity overall have greater

symptomatic manifestation with C19+ diagnosis than those participants without obesity. To test

our hypothesis, we used Bayesian linear regression and compared the sum of the symptoms

reported by participants in these samples versus samples without obesity (**Figure 5A,**

Supplementary Table 8). As predicted, among those with C19+, there is decisive evidence that

participants with obesity report a larger number of symptoms than participants without obesity

($BF_{10} = 1.02e04 \pm 0\%$; average N of symptoms = with obesity: 8.22; without obesity: 7.42). A

similar effect is observed among participants with C19- (average N of symptoms = with obesity:

8; without obesity: 7.33 $BF_{10} = 9.91e03 \pm 0\%$). Among those with C19+, disease duration is

longer in those with obesity ($BF_{10} = 1.02e04 \pm 0\%$; average days since onset), while in C19- such

a difference is not observed ($BF_{10} = 1.21e00 \pm 0\%$ (**Figure 5B, Supplementary Table 7**).

Looking at the specific symptoms (**Figure 5C**), smell and taste symptoms are equally reported

by participants with obesity and participants without obesity with a diagnosis of COVID-19.

Further, participants with self-reported obesity reported greater frequency in loss of appetite,

diarrhea, and nausea, along with shortness of breath, cough (dry or with mucus), and chest

tightness.

A classifier trained on participants without obesity accurately predicts C19+ diagnosis in

participants with obesity

Based on the self-reports on symptoms, combined with the chemosensory and nasal

obstruction ratings, we assessed the accuracy with which we could predict a C19+ diagnosis

(**Figure 6**) in OB-. We then tested the model to predict the accuracy of discrimination of C19+ in

participants with obesity. Our results indicate that we can predict the C19+ diagnosis with 63%

accuracy, which indicates a moderately good estimate. Variables included in this analysis are

reported in **Supplementary Table 8.**

DISCUSSION

Since the beginning of the COVID-19 pandemic, reports of olfactory and gustatory

dysfunctions in COVID-19 patients continue to grow. To our knowledge, this study is the first to

describe and compare the chemosensory perception and related symptomatology in COVID-19

patients who self-reported to have obesity vs. no obesity. Independent of the obesity status, the

subjective ratings of smell, taste, and chemesthesis declined with COVID-19 illness. Examining

the recovery patterns, we found that participants with obesity show similar recovery from

COVID-19 related loss of smell, taste, and chemesthesis as those without obesity. Although we

do not know the severity of each symptom, those with obesity reported a greater frequency of

respiratory and GI symptoms and more symptoms overall. Finally, we found that a model of all

symptoms combined that was trained on patients without obesity is, can predict the C19+

diagnosis with 63% of accuracy in participants with obesity. Furthermore, this smell loss was not

related to self-reported nasal obstruction, commonly observed in other upper respiratory

infections (33,34). Together, these results confirm and add to previous reports that COVID-19

largely impacts chemosensory function; however, obesity does not mask self-reported

chemosensory loss in those with a COVID diagnosis.

Smell and taste disturbances are a typical consequence of nasal inflammation due to an

upper respiratory tract viral infection (35,36); however, an acute loss of taste and smell emerged

rapidly as a critical neurological manifestation of a positive COVID-19 diagnosis (37). Our

current findings are similar to prior reports that showed that approximately 90% of the

participants reported a loss of smell. Furthermore, nearly 80% of the participants reported a loss

of taste, and 46% had a reduction of chemesthesis (detection of chemicals that induce tingling

and burning sensations such as the burning of chili peppers), indicating that the chemosensory

impairment is not restricted to smell (9,22). While most cold viruses cause nasal congestion and

individuals experience a reduction in the sense of smell, our results showed that nasal congestion

was not associated with smell loss. This finding is consistent with other reports (38–40) where

individuals with COVID-19 do not report clinically significant nasal congestion or rhinorrhea,

suggesting that other mechanisms may play a role in COVID-19 associated smell loss (37).

In addition to being a risk factor for COVID-19 viral infection, excessive body weight is

also implicated in chemosensory decline. Adipose tissue in obesity is "pro-inflammatory",

causing a surge in levels of IL-6 and C-reactive protein and enhancing the expression of

cytokines and adipokines (41). Interestingly, in diseases where these circulating inflammatory

factors are high, smell and taste dysfunction are prevalent (42,43). In particular, acute induction

of systemic inflammation has been shown to shorten the lifespan of adult taste bud cells (18).

Similarly, enhanced expression of inflammatory markers is shown to reduce olfactory sensory

neurons, in mice fed a high-fat diet to induce obesity (44). Thus, obesity-related inflammation

may affect chemosensory function. A major concern with this pre-existing gustatory and

olfactory sensory deficiency due to obesity is that obesity may mask the viral-induced

diminished taste and smell self-reported experiences. Interestingly, our analysis showed that

COVID-19 related chemosensory-related changes were comparable between C19+ participants

with obesity and without obesity suggesting that obesity does not have an effect on the loss of

chemosensory perception with COVID diagnosis. These findings need to be taken with caution,

especially when considering severe cases, which are more common in patients with obesity. For

example, if a patient is in critical condition, they cannot pay attention to their chemosensory

alterations, and chemosensory perception will likely not be tested or self-reported. This does not

mean that the chemosensory perception is not affected.

In terms of chemosensory recovery, we found no differences between participants with

obesity compared to those without obesity. While none of the studies to date have compared the

recovery rates between C19+ participants with obesity vs no obesity, our overall recovery rate of

65% is comparable to our previous analysis (9) but slightly lower than other studies (45,46).

There are residuals smell/taste/chemosensory symptoms reported post-recovery from the illness

in C19+ and C19- groups. In particular, quantitative studies using psychophysical methods have

shown that nearly 25% of people continue to report chemosensory problems when evaluated 30 -

60 days after the onset of COVID-19 (45). This insufficient recovery rate may significantly

increase the number of patients with chemosensory disturbances, ultimately influencing eating

behaviors (47), quality of life (48,49), and psychological health (50,51) in the general population.

But most importantly, it may significantly impact participants with obesity who have an added

burden of lower chemosensory acuity due to excess fat mass (44,52). Thus, it is imperative to

prepare healthcare workers to detect and treat chemosensory disorders in this high-risk

population.

As we hypothesized, non-chemosensory symptoms were more severe in C19+

participants with obesity than in participants without obesity. Specifically, participants with

obesity reported a greater frequency of respiratory and GI symptoms. In general, it is known that

obesity is associated with GI symptoms disturbances, such as upper abdominal pain, nausea,

vomiting, retching, and gastritis. GI symptoms are accompanied by inflammation or alterations

of intestinal permeability (53–56). However, it also emerged that COVID-19 patients

experienced several GI symptoms such as diarrhea (24.2%), anorexia (17.9%), and nausea

(17.9%) (57), though they vary widely and are less understood. However, this may not be

surprising since some viral infections are known to cause alterations in intestinal permeability as

well (58). The mediation of ACE2 cell receptors could elucidate the mechanism related to GI

tract involvement in SARS-CoV-2 infection. While ACE2 is expressed in abundance in the

lungs' alveolar cells, the receptor is also highly expressed in the GI tract, especially in the small

and large intestines (59–63).

Our study has some limitations. Our online survey and sampling methodology likely

selected participants with a heightened interest in smell and taste and/or their disturbances. Due

to that, the data collected at the peak of the pandemic obesity was self-reported; thus, we

acknowledge the potential under-reporting of obesity. We also acknowledge that due to the

nature of our data being collected in several countries, the definition of obesity may vary and

there may be regional and cultural factors that may influence stigma and biases towards self-

report of obesity. Ideally, future studies using quantitative taste and smell measures will be

conducted in this population. However, although the taste and smell reports were also self-

reports, similar to prior studies, we demonstrate that self-reported taste and smell may be a

helpful tool to distinguish between C19+ and C19–.

Despite the limitations, our study shows differences in participants with obesity

compared to participants without obesity with other symptoms. However, those differences

potentially do not affect the chemosensory symptoms. In general, more evidence is needed to

understand biological mechanisms related to alterations in taste and smell loss in individuals

with COVID-19. Understanding how the alteration initiates and progresses will provide

molecular and cellular bases for diagnosis and treatment of chemosensory disorders for those

with COVID-19 and others who lose their sense of taste and smell due to other conditions with

underlying inflammation. While it is an exciting prospect, the use of chemosensory assessments

as an effective tool for screening and treatment protocols, and the possibility of integrating these

tests into current COVID-19 screening protocols have yet to be determined in the general

population, as well as high-risk populations with obesity.

Acknowledgments

The authors wish to thank all study participants, patients, and patient advocates that have

contributed to this project.

REFERENCES

1.   Obesity and overweight [Internet]. World Health Organization Fact Sheet Obesity and

Overweight. 2021 [cited 2021 Jan 25]. Available from: https://www.who.int/news-

room/fact-sheets/detail/obesity-and-overweight

2.   Max Roser EO-O Hannah Ritchie, Hasell J. Coronavirus Pandemic (COVID-19). Our

World Data. 2020;

3.   Stefan N, Birkenfeld AL, Schulze MB. Global pandemics interconnected - obesity,

impaired metabolic health and COVID-19. Nat Rev Endocrinol. 2021 Jan 21;

4.   Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors

associated with COVID-19-related death using OpenSAFELY. Nature. 2020

Aug;584(7821):430–6.

5.   Kalligeros M, Shehadeh F, Mylona EK, Benitez G, Beckwith CG, Chan PA, et al.

Association of Obesity with Disease Severity Among Patients with Coronavirus Disease

2019. Obesity. 2020;28(7):1200–4.

6.   Zhu X, Yang L, Huang K. COVID-19 and Obesity: Epidemiology, Pathogenesis and

Treatment. Diabetes Metab Syndr Obes Targets Ther. 2020 Dec 14;13:4953–9.

7.   Lighter J, Phillips M, Hochman S, Sterling S, Johnson D, Francois F, et al. Obesity in

Patients Younger Than 60 Years Is a Risk Factor for COVID-19 Hospital Admission. Clin

Infect Dis Off Publ Infect Dis Soc Am. 2020 28;71(15):896–7.

8.   Hannum ME, Ramirez VA, Lipson SJ, Herriman RD, Toskala AK, Lin C, et al. Objective

Sensory Testing Methods Reveal a Higher Prevalence of Olfactory Loss in COVID-19–

Positive Patients Compared to Subjective Methods: A Systematic Review and Meta-

Analysis. Chem Senses. 2020 Dec 5;45(9):865–74.

9.   Gerkin RC, Ohla K, Veldhuizen MG, Joseph PV, Kelly CE, Bakke AJ, et al. Recent smell

loss is the best predictor of COVID-19 among individuals with recent respiratory

symptoms. Chem Senses [Internet]. 2020 Dec 25 [cited 2021 Jan 13];(bjaa081). Available

from: https://doi.org/10.1093/chemse/bjaa081

10. Uygun B, Kiyici S, Ozmen S, Gul Z, Sigirli D, Cavun S. The Association Between

Olfaction and Taste Functions with Serum Ghrelin and Leptin Levels in Obese Women.

Metab Syndr Relat Disord. 2019 Nov;17(9):452–7.

11. Tucker RM, Edlinger C, Craig BA, Mattes RD. Associations Between BMI and Fat Taste

Sensitivity in Humans. Chem Senses. 2014 May 1;39(4):349–57.

12. Bertoli S, Laureati M, Battezzati A, Bergamaschi V, Cereda E, Spadafranca A, et al. Taste

sensitivity, nutritional status and metabolic syndrome: Implication in weight loss dietary

interventions. World J Diabetes. 2014 Oct 15;5(5):717–23.

13. Low JYQ, Lacy KE, McBride R, Keast RSJ. The Association between Sweet Taste

Function, Anthropometry, and Dietary Intake in Adults. Nutrients. 2016 Apr 23;8(4):241.

14.   Fernández-Aranda F, Agüera Z, Fernández-García JC, Garrido-Sanchez L, Alcaide-Torres

459   J, Tinahones FJ, et al. Smell-taste dysfunctions in extreme weight/eating conditions:

460   analysis of hormonal and psychological interactions. Endocrine. 2016 Feb;51(2):256–67.

461   15.   Fernandez-Garcia JC, Alcaide J, Santiago-Fernandez C, Roca-Rodriguez MM, Aguera Z,

462   Baños R, et al. An increase in visceral fat is associated with a decrease in the taste and

463   olfactory capacity. PloS One. 2017;12(2):e0171204.

464   16.   Thiebaud N, Johnson MC, Butler JL, Bell GA, Ferguson KL, Fadool AR, et al.

465   Hyperlipidemic diet causes loss of olfactory sensory neurons, reduces olfactory

466   discrimination, and disrupts odor-reversal learning. J Neurosci Off J Soc Neurosci. 2014

467   May 14;34(20):6970–84.

468   17.   Besnard P, Passilly-Degrace P, Khan NA. Taste of Fat: A Sixth Taste Modality? Physiol

469   Rev. 2016 Jan;96(1):151–76.

470   18.   Kaufman A, Choo E, Koh A, Dando R. Inflammation arising from obesity reduces taste bud

471   abundance and inhibits renewal. PLOS Biol. 2018 Mar 20;16(3):e2001959.

472   19.   Huttunen R, Syrjänen J. Obesity and the outcome of infection. Lancet Infect Dis. 2010

473   Jul;10(7):442–3.

474   20.   Nave H, Beutel G, Kielstein JT. Obesity-related immunodeficiency in patients with

475   pandemic influenza H1N1. Lancet Infect Dis. 2011 Jan;11(1):14–5.

476   21.   Khan AS, Hichami A, Khan NA. Obesity and COVID-19: Oro-Naso-Sensory Perception. J

477   Clin Med. 2020 Jul;9(7):2158.

478   22.   Parma V, Ohla K, Veldhuizen MG, Niv MY, Kelly CE, Bakke AJ, et al. More Than

479   Smell—COVID-19 Is Associated With Severe Impairment of Smell, Taste, and

480   Chemesthesis. Chem Senses. 2020 Oct 9;45(7):609–22.

23. Menni C, Valdes AM, Freidin MB, Sudre CH, Nguyen LH, Drew DA, et al. Real-time

tracking of self-reported symptoms to predict potential COVID-19. Nat Med.

2020;26:1037–40.

24. Foster KJ, Jauregui E, Tajudeen B, Bishehsari F, Mahdavinia M. Smell loss is a prognostic

factor for lower severity of coronavirus disease 2019. Ann Allergy Asthma Immunol. 2020

Oct 1;125(4):481–3.

25. Reiner RC, Barber RM, Collins JK, Zheng P, Adolph C, Albright J, et al. Modeling

COVID-19 scenarios for the United States. Nat Med. 2020 Oct 23;1–12.

26. Bhutani S, Parma V, Joseph PV, Coppin G, Veldhuizen M. Chemosensory dysfunction as a

reliable marker for COVID-19 in adults with self-reported obesity [Internet]. 2020.

Available from: osf.io/xf25v

27. Team R Core Development. R: The R Project for Statistical Computing [Internet]. 2013

[cited 2021 Feb 9]. Available from: https://www.r-project.org/

28. Morey RD, Rouder JN, Jamil T, Urbanek S, Forner K, Ly A. BayesFactor: Computation of

Bayes Factors for Common Designs [Internet]. 2018 [cited 2021 Feb 9]. Available from:

https://CRAN.R-project.org/package=BayesFactor

29. Lee MD, Wagenmakers E-J. Bayesian Cognitive Modeling: A Practical Course [Internet].

Cambridge: Cambridge University Press; 2013 [cited 2020 Jul 19]. Available from:

http://ebooks.cambridge.org/ref/id/CBO9781139087759

30. Jeffreys H. The Theory of Probability. OUP Oxford; 1998. 474 p.

31. Lunardon N, Menardi G, Torelli N. ROSE: a Package for Binary Imbalanced Learning. R J.

2014;6(1):79.

32. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J-C, et al. pROC: an open-

source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics.

2011 Mar 17;12(1):77.

33. Akerlund A, Bende M, Murphy C. Olfactory threshold and nasal mucosal changes in

experimentally induced common cold. Acta Otolaryngol (Stockh). 1995 Jan;115(1):88–92.

34. Doty RL, Mishra A. Olfaction and Its Alteration by Nasal Obstruction, Rhinitis, and

Rhinosinusitis. The Laryngoscope. 2001;111(3):409–23.

35. Soler ZM, Patel ZM, Turner JH, Holbrook EH. A primer on viral-associated olfactory loss

in the era of COVID-19. Int Forum Allergy Rhinol. 2020;10(7):814–20.

36. Hummel T, Landis BN, Hüttenbrink K-B. Smell and taste disorders. GMS Curr Top

Otorhinolaryngol Head Neck Surg. 2011;10:Doc04.

37. Cooper KW, Brann DH, Farruggia MC, Bhutani S, Pellegrino R, Tsukahara T, et al.

COVID-19 and the chemical senses: supporting players take center stage. Neuron

[Internet]. 2020 Jul [cited 2020 Jul 2]; Available from:

https://linkinghub.elsevier.com/retrieve/pii/S0896627320304864

38. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic Manifestations of

Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China [Internet]. JAMA

Neurology. 2020. Available from:

https://jamanetwork.com/journals/jamaneurology/fullarticle/2764549

39. Mao L, Wang M, Chen S, He Q, Chang J, Hong C, et al. Neurological Manifestations of

Hospitalized Patients with COVID-19 in Wuhan, China: a retrospective case series study.

medRxiv. 2020;2020.02.22.20026500.

40. Li Y, Bai W, Hashikawa T. The neuroinvasive potential of SARS☐CoV2 may be at least

partially responsible for the respiratory failure of COVID☐19 patients [Internet]. Journal of

Medical Virology. 2020. Available from:

https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.25728

41. Heredia FP de, Gómez-Martínez S, Marcos A. Obesity, inflammation and the immune

system. Proc Nutr Soc. 2012 May;71(2):332–8.

42. Rawson NE, Huang L. Symposium Overview. Ann N Y Acad Sci. 2009;1170(1):581–4.

43. Wang H, Zhou M, Brand J, Huang L. Inflammation and Taste Disorders. Vol. 1170, Annals

of the New York Academy of Sciences. 2009. p. 596–603.

44. Riera CE, Tsaousidou E, Halloran J, Follett P, Hahn O, Pereira MMA, et al. The Sense of

Smell Impacts Metabolic Health and Obesity. Cell Metab. 2017 Jul 5;26(1):198-211.e5.

45. Niklassen AS, Draf J, Huart C, Hintschich C, Bocksberger S, Trecca EMC, et al. COVID-

19: Recovery from Chemosensory Dysfunction. A Multicentre study on Smell and Taste.

The Laryngoscope. 2021 Jan 6;

46. Reiter ER, Coelho DH, Kons ZA, Costanzo RM. Subjective smell and taste changes during

the COVID-19 pandemic: Short term recovery. Am J Otolaryngol. 2020 Dec;41(6):102639.

47. Kershaw JC, Mattes RD. Nutrition and taste and smell dysfunction. World J

Otorhinolaryngol - Head Neck Surg. 2018 Mar 1;4(1):3–10.

48. Smeets MAM, Veldhuizen MG, Galle S, Gouweloos J, de Haan A-MJA, Vernooij J, et al.

Sense of smell disorder and health-related quality of life. Rehabil Psychol. 2009

Nov;54(4):404–12.

49. Croy I, Nordin S, Hummel T. Olfactory disorders and quality of life--an updated review.

Chem Senses. 2014 Mar;39(3):185–94.

50. Malaty J, Malaty IAC. Smell and taste disorders in primary care. Am Fam Physician. 2013

Dec 15;88(12):852–9.

51. Croy I, Symmank A, Schellong J, Hummel C, Gerber J, Joraschky P, et al. Olfaction as a

marker for depression in humans. J Affect Disord. 2014 May 1;160:80–6.

52. Peng M, Coutts D, Wang T, Cakmak YO. Systematic review of olfactory shifts related to

obesity. Obes Rev. 2019;20(2):325–38.

53. Nam SY. Obesity-Related Digestive Diseases and Their Pathophysiology. Gut Liver. 2017

May 15;11(3):323–34.

54. Camilleri M, Malhi H, Acosta A. Gastrointestinal Complications of Obesity.

Gastroenterology. 2017 May 1;152(7):1656–70.

55. Nagpal R, Newman TM, Wang S, Jain S, Lovato JF, Yadav H. Obesity-Linked Gut

Microbiome Dysbiosis Associated with Derangements in Gut Permeability and Intestinal

Cellular Homeostasis Independent of Diet. Fiorina P, editor. J Diabetes Res. 2018 Sep

3;2018:3462092.

56. Moss O, Keshavarzian A, Tangney C, Shawron K, Kester K, Shaikh M, et al. Headache, GI

symptoms and Intestinal Permeability in Obese Adults. FASEB J. 2016;30(S1):1166.7-

1166.7.

57. Lin L, Jiang X, Zhang Z, Huang S, Zhang Z, Fang Z, et al. Gastrointestinal symptoms of 95

cases with SARS-CoV-2 infection. Gut. 2020 Jun 1;69(6):997–1001.

58. Labarta-Bajo L, Nilsen SP, Humphrey G, Schwartz T, Sanders K, Swafford A, et al. Type I

IFNs and CD8 T cells increase intestinal barrier permeability after chronic viral infection. J

Exp Med [Internet]. 2020 Sep 3 [cited 2021 Feb 19];217(e20192276). Available from:

https://doi.org/10.1084/jem.20192276

59. Jin X, Lian J-S, Hu J-H, Gao J, Zheng L, Zhang Y-M, et al. Epidemiological, clinical and

virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19)

with gastrointestinal symptoms. Gut. 2020 Jun;69(6):1002–9.

60.   Parasa S, Desai M, Thoguluva Chandrasekar V, Patel HK, Kennedy KF, Roesch T, et al.

Prevalence of Gastrointestinal Symptoms and Fecal Viral Shedding in Patients With

Coronavirus Disease 2019: A Systematic Review and Meta-analysis. JAMA Netw Open.

2020 Jun 11;3(6):e2011335–e2011335.

61.   Villapol S. Gastrointestinal symptoms associated with COVID-19: impact on the gut

microbiome. Transl Res. 2020 Dec 1;226:57–69.

62.   Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, Goor H van. Tissue distribution

of ACE2 protein, the functional receptor for SARS coronavirus. A first step in

understanding SARS pathogenesis. J Pathol. 2004;203(2):631–7.

63.   Li M-Y, Li L, Zhang Y, Wang X-S. Expression of the SARS-CoV-2 cell receptor gene

ACE2 in a wide variety of human tissues. Infect Dis Poverty. 2020 Apr 28;9(1):45.

FIGURE LEGENDS

Figure 1. Flow Diagram of Study Participants Based on the STrengthening the Reporting of

OBservational Studies in Epidemiology (STROBE) guidelines. Participants included in the

prediction of COVID-19 status in participants with obesity vs without obesity are framed in blue.

Participants framed in purple are included in all other analyses. n = number of participants; OB+

= self-reported presence of obesity; OB- = self-reported presence of obesity; COVID diagnosis

unclear = responses "No - I do not have any symptoms", "Don't know" or "Other" to survey

Question 8 ("Have you been diagnosed with COVID-19?").

Figure 2. Self-reported smell (A), taste (B), chemesthesis (C), and nasal obstruction (D) ratings

during the illness in C19+ (in purple) and C19- (in blue) participants with obesity (OB+) or

without obesity (OB-). Ratings were given on 0-100 visual analog scales. Nasal obstruction

question was formulated as "How blocked was your nose?") during respiratory illness in C19+

and C19- participants. Each panel presents the mean ratings for chemosensory abilities and nasal

blockage. All participants had a diagnosis via a lab test. The thick black horizontal bar indicates

the median, the shaded bars within each violin indicates the interquartile range. The shaded

violin area in purple and blue represents smoothed histogram of data density along the data

points.

Figure 3. Self-reported change in smell (A), taste (B), chemesthesis (C), and nasal obstruction

(D) ratings in C19+ (in purple) and C19- (in blue) participants with obesity (OB+) or without

obesity (OB-). Each panel presents the distribution of the change scores, i.e., the rating "before"

illness minus the rating "during" illness on the 100-point visual analog scale. All participants had

a diagnosis via a lab test. The thick black horizontal bar indicates the median, the shaded bars

within each violin indicates the interquartile range. The shaded violin area in purple and blue

represents smoothed histogram of data density along the data points.

Figure 4. Self-reported change in smell (A), taste (B), chemesthesis (C), and nasal obstruction

(D) ratings post-recovery from respiratory illness in C19+ (in purple) and C19- (in blue)

participants with obesity (OB+) or without obesity (OB-). Ratings were given on 0-100 visual

analog scales. Each panel presents the mean ratings for chemosensory abilities and nasal

blockage post-recovery from respiratory illness. All participants had a diagnosis via a lab

test. The thick black horizontal bar indicates the median, the shaded bars within each violin

indicates the interquartile range. The shaded violin area in purple and blue represents smoothed

histogram of data density along the data points.

Figure 5. Self-reported symptomatic manifestation reported by C19+ (in purple) and C19- (in

blue) participants with obesity (OB+) or without obesity (OB-). **(A)** Cumulative number of

symptoms reported by C19+ (in purple) and C19- (in blue) participants with obesity (OB+) or

without obesity (OB-).

(B) Self-reported average number of days since onset of respiratory illness symptoms reported

by C19+ (in purple) and C19- (in blue) participants with obesity (OB+) or without obesity (OB-).

(C) Proportion of participants with C19+ that report specific symptoms by self-reported obesity

(OB+) or without obesity (OB-). * p<0.05. The thick black horizontal bar indicates the median,

the shaded bars within each violin indicates the interquartile range. The shaded violin area in

purple and blue represents smoothed histogram of data density along the data points.

Figure 6. ROC curve in discriminating C19+ vs. C19- in participants with obesity (OB+) after

having trained the model with participants without obesity (OB-).